JP2012517428A - Ｔｏｌｌ様レセプター調節因子および疾患の処置 - Google Patents

Ｔｏｌｌ様レセプター調節因子および疾患の処置 Download PDF

Info

Publication number
JP2012517428A
JP2012517428A JP2011549168A JP2011549168A JP2012517428A JP 2012517428 A JP2012517428 A JP 2012517428A JP 2011549168 A JP2011549168 A JP 2011549168A JP 2011549168 A JP2011549168 A JP 2011549168A JP 2012517428 A JP2012517428 A JP 2012517428A
Authority
JP
Japan
Prior art keywords
alkyl
acid
compound
substituted
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011549168A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012517428A5 (https=
Inventor
デニス エー． カーソン，
ハワード ビー． コタム，
公子 林
マイケル チャン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
University of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California filed Critical University of California
Publication of JP2012517428A publication Critical patent/JP2012517428A/ja
Publication of JP2012517428A5 publication Critical patent/JP2012517428A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/24—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one nitrogen and one sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pretreatment Of Seeds And Plants (AREA)
JP2011549168A 2009-02-11 2010-02-11 Ｔｏｌｌ様レセプター調節因子および疾患の処置 Pending JP2012517428A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15173709P 2009-02-11 2009-02-11
US61/151,737 2009-02-11
PCT/US2010/000369 WO2010093436A2 (en) 2009-02-11 2010-02-11 Toll-like receptor modulators and treatment of diseases

Publications (2)

Publication Number Publication Date
JP2012517428A true JP2012517428A (ja) 2012-08-02
JP2012517428A5 JP2012517428A5 (https=) 2013-02-21

Family

ID=42173783

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011549168A Pending JP2012517428A (ja) 2009-02-11 2010-02-11 Ｔｏｌｌ様レセプター調節因子および疾患の処置

Country Status (14)

Country Link
US (1) US8729088B2 (https=)
EP (2) EP2607365A1 (https=)
JP (1) JP2012517428A (https=)
KR (1) KR20110117705A (https=)
CN (1) CN102439011B (https=)
AU (1) AU2010214112B2 (https=)
BR (1) BRPI1008383A2 (https=)
CA (1) CA2752074A1 (https=)
EA (1) EA019768B1 (https=)
IL (1) IL214572A (https=)
MX (1) MX2011008500A (https=)
SG (1) SG173617A1 (https=)
WO (1) WO2010093436A2 (https=)
ZA (1) ZA201106268B (https=)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9050376B2 (en) 2007-02-07 2015-06-09 The Regents Of The University Of California Conjugates of synthetic TLR agonists and uses therefor
US9359360B2 (en) 2005-08-22 2016-06-07 The Regents Of The University Of California TLR agonists
WO2020204173A1 (ja) * 2019-04-05 2020-10-08 大日本住友製薬株式会社 水溶性アジュバントおよびそれを含有する組成物
JPWO2020204172A1 (https=) * 2019-04-05 2020-10-08
JP2020531472A (ja) * 2017-08-16 2020-11-05 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 免疫刺激因子トル様受容体７（ｔｌｒ７）アゴニストとしての、６−アミノ−７，９−ジヒドロ−８ｈ−プリン−８−オン誘導体
JP2020531469A (ja) * 2017-08-16 2020-11-05 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 三環式基を有するトル様受容体７（ｔｌｒ７）アゴニスト、そのコンジュゲート、ならびにそれらの方法および使用
JP2021501765A (ja) * 2017-11-06 2021-01-21 サントル ナショナル ドゥ ラ ルシェルシュ シアンティフィック キサンチン誘導体及びｂｅｔタンパク質のブロモドメインの阻害剤としてのその使用
US11697851B2 (en) 2016-05-24 2023-07-11 The Regents Of The University Of California Early ovarian cancer detection diagnostic test based on mRNA isoforms

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2029597A4 (en) 2006-05-31 2011-11-23 Univ California purine analogs
EP2038290B1 (en) * 2006-07-07 2013-09-04 Gilead Sciences, Inc. Modulators of toll-like receptor 7
EA201001264A1 (ru) * 2008-02-07 2011-04-29 Дзе Регентс Оф Дзе Юниверсити Оф Калифорния Способ лечения заболеваний мочевого пузыря с помощью активатора tlr7
ES2467108T3 (es) 2008-12-09 2014-06-11 Gilead Sciences, Inc. Moduladores de receptores tipo toll
WO2010088924A1 (en) 2009-02-06 2010-08-12 Telormedix Sa Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration
KR20110117705A (ko) 2009-02-11 2011-10-27 더 리전트 오브 더 유니버시티 오브 캘리포니아 톨-유사 수용체 조정제 및 질병의 치료
WO2010115229A1 (en) 2009-04-09 2010-10-14 The University Of Melbourne Immunogenic composition and uses thereof
US8962652B2 (en) 2009-10-22 2015-02-24 Gilead Sciences, Inc. Derivatives of purine or deazapurine useful for the treatment of (inter alia) viral infections
NZ603155A (en) 2010-04-30 2014-06-27 Telormedix Sa Phospholipid drug analogs
US9050319B2 (en) 2010-04-30 2015-06-09 Telormedix, Sa Phospholipid drug analogs
US20130202629A1 (en) * 2010-04-30 2013-08-08 The Regents Of The University Of California Uses of phospholipid conjugates of synthetic tlr7 agonists
US20120083473A1 (en) * 2010-09-21 2012-04-05 Johanna Holldack Treatment of conditions by toll-like receptor modulators
DK2618842T3 (da) 2010-09-22 2019-07-01 Ena Therapeutics Pty Ltd Hidtil ukendt immunstimulerende fremgangsmåde
GB201022049D0 (en) * 2010-12-29 2011-02-02 Imp Innovations Ltd Methods
DK2663550T3 (en) 2011-01-12 2017-03-27 Ventirx Pharmaceuticals Inc SUBSTITUTED BENZOAZEPINS AS MODULATORS OF TOLL-LIKE RECEPTORS
TW201247706A (en) * 2011-03-08 2012-12-01 Baylor Res Inst Novel vaccine adjuvants based on targeting adjuvants to antibodies directly to antigen-presenting cells
WO2012167053A1 (en) 2011-06-01 2012-12-06 Janus Biotherapeutics, Inc. Novel immune system modulators
GB201205360D0 (en) * 2012-03-27 2012-05-09 Univ Edinburgh Biotinidase resistant biotinyl compounds
CN103254304A (zh) * 2012-05-30 2013-08-21 深圳大学 免疫激动剂偶联体、其制备方法及免疫激动剂偶联体在抗肿瘤中的应用
EP2674170B1 (en) 2012-06-15 2014-11-19 Invivogen Novel compositions of TLR7 and/or TLR8 agonists conjugated to lipids
WO2014052828A1 (en) 2012-09-27 2014-04-03 The Regents Of The University Of California Compositions and methods for modulating tlr4
CN102993265B (zh) * 2012-10-10 2015-05-13 深圳大学 免疫受体调节剂偶联体及其制备方法和应用、制备其的偶联前体以及合成偶联前体的化合物
EP2732825B1 (en) 2012-11-19 2015-07-01 Invivogen Conjugates of a TLR7 and/or TLR8 agonist and a TLR2 agonist
US9295732B2 (en) 2013-02-22 2016-03-29 Invivogen Conjugated TLR7 and/or TLR8 and TLR2 polycationic agonists
EP2769738B1 (en) 2013-02-22 2016-07-20 Invivogen Conjugated TLR7 and/or TLR8 and TLR2 polycationic agonists
CN103467590B (zh) * 2013-09-02 2016-04-13 深圳大学 生物偶联体、制备其的嘌呤类化合物、合成方法、药用制剂以及其在免疫调节中的应用
MX377916B (es) 2014-04-22 2025-03-10 Hoffmann La Roche Compuestos 4-amino-imidazoquinolina.
EA032487B1 (ru) * 2014-05-01 2019-06-28 Новартис Аг Соединения и композиции в качестве агонистов toll-подобного рецептора 7
PT3166607T (pt) 2014-07-11 2022-12-07 Gilead Sciences Inc Moduladores de receptores de tipo toll para o tratamento do vih
CA2960436C (en) 2014-09-16 2021-01-05 Gilead Sciences, Inc. Solid forms of a toll-like receptor modulator
KR102581546B1 (ko) 2015-03-06 2023-09-25 에프. 호프만-라 로슈 아게 벤즈아제핀 다이카복스아미드 화합물
CN108055842B (zh) 2015-09-17 2021-06-29 豪夫迈·罗氏有限公司 亚磺酰基苯基或磺亚胺酰基苯基苯并氮杂䓬
ES2805724T3 (es) 2015-09-29 2021-02-15 Sumitomo Dainippon Pharma Co Ltd Compuestos de adenina conjugados y su uso como adyuvantes de vacunas
SG11201802832UA (en) 2015-10-07 2018-05-30 Sumitomo Dainippon Pharma Co Ltd Pyrimidine compound
CA3005766A1 (en) 2015-12-17 2017-06-22 Merck Patent Gmbh Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders
EP3464274B1 (en) 2016-05-23 2020-05-27 H. Hoffnabb-La Roche Ag Benzazepine dicarboxamide compounds with secondary amide function
JP6918838B2 (ja) 2016-05-23 2021-08-11 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 第三級アミド基を有するベンズアゼピンジカルボキサミド化合物
JP7012668B2 (ja) 2016-06-12 2022-02-14 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト ジヒドロピリミジニルベンズアゼピンジカルボキサミド化合物
JP7125385B2 (ja) 2016-08-08 2022-08-24 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｔｌｒ７／８アンタゴニストおよびそれらの使用
CN106267188B (zh) * 2016-08-15 2025-06-17 深圳大学 小分子免疫激动剂偶联pd-1抗体的新型抗体及其在抗肿瘤中的应用
US10494370B2 (en) 2017-08-16 2019-12-03 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a pyridine or pyrazine moiety, conjugates thereof, and methods and uses therefor
US10508115B2 (en) 2017-08-16 2019-12-17 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having heteroatom-linked aromatic moieties, conjugates thereof, and methods and uses therefor
US10487084B2 (en) 2017-08-16 2019-11-26 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a heterobiaryl moiety, conjugates thereof, and methods and uses therefor
WO2019057158A1 (zh) * 2017-09-22 2019-03-28 江苏恒瑞医药股份有限公司 稠合杂芳基衍生物、其制备方法及其在医药上的应用
EP3728289B1 (en) 2017-12-21 2025-09-10 Axelia Oncology Pty Ltd Optimised compounds
CN108379591B (zh) * 2018-04-03 2022-03-29 深圳大学 免疫激动剂靶向化合物的合成及其应用
WO2019209811A1 (en) 2018-04-24 2019-10-31 Bristol-Myers Squibb Company Macrocyclic toll-like receptor 7 (tlr7) agonists
CA3107409A1 (en) 2018-07-23 2020-01-30 Japan As Represented By Director General Of National Institute Of Infectious Diseases Composition containing influenza vaccine
US11554120B2 (en) 2018-08-03 2023-01-17 Bristol-Myers Squibb Company 1H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists and methods and uses therefor
WO2020097396A1 (en) 2018-11-07 2020-05-14 Dana-Farber Cancer Institute, Inc. Benzimidazole derivatives and aza-benzimidazole derivatives as janus kinase 2 inhibitors and uses thereof
WO2020097398A1 (en) 2018-11-07 2020-05-14 Dana-Farber Cancer Institute, Inc. Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof
EP3877371A4 (en) 2018-11-07 2022-07-27 Dana-Farber Cancer Institute, Inc. IMIDAZOPYRIDINE DERIVATIVES AND AZA-IMIDAZOPYRIDINE DERIVATIVES AS JANUS KINASE 2 INHIBITORS AND USES THEREOF
JP7637328B2 (ja) * 2019-02-07 2025-02-28 ベイジーン リミテッド Ｔｌｒ７アゴニストとしてのイミダゾ［２，１－ｆ］［１，２，４］トリアジン－４－アミン誘導体
MX2021014353A (es) 2019-05-23 2022-02-21 The Univ Of Montana Adyuvantes de vacunas basados en ligandos de receptores tlr.
US20220305115A1 (en) 2019-06-18 2022-09-29 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and pyridopyrimidine derivatives
KR20220050873A (ko) 2019-06-26 2022-04-25 악셀리아 온콜로지 피티와이 리미티드 신규한 분자
EP4008720A4 (en) * 2019-08-02 2023-08-02 BeiGene, Ltd. IMIDAZO [2,1-F][1,2,4] TRIAZINE-4-AMINE DERIVATIVES AS A TLR8 AGONIST
EP4013880A1 (en) 2019-08-14 2022-06-22 CureVac AG Rna combinations and compositions with decreased immunostimulatory properties
WO2021084022A1 (en) 2019-10-31 2021-05-06 F. Hoffmann-La Roche Ag Hydropyrazino[1,2-d][1,4]diazepine compounds for the treatment of autoimmune disease
CN114728976B (zh) 2019-11-19 2024-08-16 豪夫迈·罗氏有限公司 用于治疗自身免疫性疾病的氢-1H-吡咯并[1,2-a]吡嗪化合物
WO2021154663A1 (en) 2020-01-27 2021-08-05 Bristol-Myers Squibb Company 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS
JP2023512204A (ja) 2020-01-27 2023-03-24 ブリストル－マイヤーズ スクイブ カンパニー トール様受容体７（ＴＬＲ７）アゴニストとしての１Ｈ－ピラゾロ［４，３－ｄ］ピリミジン化合物
US20230348468A1 (en) 2020-01-27 2023-11-02 Bristol-Myers Squibb Company 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS
CN115151546A (zh) 2020-01-27 2022-10-04 百时美施贵宝公司 作为Toll样受体7(TLR7)激动剂的C3-取代的1H-吡唑并[4,3-d]嘧啶化合物
US20230131192A1 (en) 2020-01-27 2023-04-27 Bristol-Myers Squibb Company 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS
US12485123B2 (en) 2020-01-27 2025-12-02 Bristol-Myers Squibb Company 1H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists
KR20220132601A (ko) 2020-01-27 2022-09-30 브리스톨-마이어스 스큅 컴퍼니 톨-유사 수용체 7 (TLR7) 효능제로서의 1H-피라졸로[4,3-d]피리미딘 화합물
US20230144824A1 (en) 2020-01-27 2023-05-11 Bristol-Myers Squibb Company 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS
KR20220132589A (ko) 2020-01-27 2022-09-30 브리스톨-마이어스 스큅 컴퍼니 톨-유사 수용체 7 (TLR7) 효능제로서의 1H-피라졸로[4,3-d]피리미딘 화합물
JP7735291B2 (ja) 2020-02-21 2025-09-08 エーアールエス ファーマシューティカルズ、インコーポレイテッド ネクチン－４抗体コンジュゲートおよびその使用
CN111704614B (zh) * 2020-04-15 2021-10-22 深圳大学 一种系列免疫激动剂
CA3181537A1 (en) 2020-05-06 2021-11-11 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
JP2023532304A (ja) 2020-07-01 2023-07-27 エーアールエス ファーマシューティカルズ オペレーションズ，インク． 抗ａｓｇｒ１抗体コンジュゲートおよびその使用
CN114315861A (zh) * 2020-09-27 2022-04-12 上海维申医药有限公司 大环tlr7激动剂、其制备方法、药物组合物及其用途
CA3196221A1 (en) 2020-10-21 2022-04-28 Univerza V Ljubljani Conjugated tlr7 and nod2 agonists
EP4267574B1 (en) 2020-12-23 2025-04-23 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
JP7753397B2 (ja) * 2021-05-26 2025-10-14 ノバルティス アーゲー ウェルナー症候群ＲｅｃＱヘリカーゼ（ＷＲＮ）の阻害に関連する疾患を治療するためのトリアゾロ－ピリミジン類似体
JP7782035B2 (ja) 2021-11-09 2025-12-08 エイジャックス セラピューティクス， インコーポレイテッド Ｊａｋ２阻害剤としての６－ヘテロアリールオキシベンゾイミダゾール及びアザベンゾイミダゾール
TW202325289A (zh) 2021-11-09 2023-07-01 美商雅捷可斯治療公司 Ｊａｋ２抑制劑之形式及組合物
JP2025540756A (ja) * 2022-12-05 2025-12-16 江蘇恒瑞医薬股▲ふん▼有限公司 トリアゾール化合物、その製造方法と医薬的用途
CN121358739A (zh) * 2023-06-12 2026-01-16 抟相医药(上海)有限公司 新型化合物，包含其的组合物及其用途
WO2025040743A1 (en) 2023-08-22 2025-02-27 Univerza V Ljubljani Conjugated tlr7 and rig-i agonists
WO2025093657A1 (en) 2023-10-31 2025-05-08 Univerza V Ljubljani Conjugated tlr7 and tlr4 agonists
CN120424093A (zh) * 2024-02-02 2025-08-05 中国科学院上海药物研究所 螺环类化合物、包含其的药物组合物及其用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004029054A1 (ja) * 2002-09-27 2004-04-08 Sumitomo Pharmaceuticals Company, Limited 新規アデニン化合物及びその用途

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2699908A (en) 1955-01-18 fletcher
IL73534A (en) * 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
CA1271477A (en) 1983-11-18 1990-07-10 John F. Gerster 1h-imidazo[4,5-c]quinolin-4-amines
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
US5238944A (en) * 1988-12-15 1993-08-24 Riker Laboratories, Inc. Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
US5736553A (en) * 1988-12-15 1998-04-07 Riker Laboratories, Inc. Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo 4,5-C!quinolin-4-amine
US4929624A (en) * 1989-03-23 1990-05-29 Minnesota Mining And Manufacturing Company Olefinic 1H-imidazo(4,5-c)quinolin-4-amines
US5037986A (en) * 1989-03-23 1991-08-06 Minnesota Mining And Manufacturing Company Olefinic 1H-imidazo[4,5-c]quinolin-4-amines
NZ232740A (en) 1989-04-20 1992-06-25 Riker Laboratories Inc Solution for parenteral administration comprising a 1h-imidazo(4,5-c) quinolin-4-amine derivative, an acid and a tonicity adjuster
DK0553202T3 (da) 1990-10-05 1995-07-03 Minnesota Mining & Mfg Fremgangsmåde til fremstilling af imidazo(4,5-c)quinolin-4-aminer
US5175296A (en) 1991-03-01 1992-12-29 Minnesota Mining And Manufacturing Company Imidazo[4,5-c]quinolin-4-amines and processes for their preparation
IL105325A (en) 1992-04-16 1996-11-14 Minnesota Mining & Mfg Immunogen/vaccine adjuvant composition
US5395937A (en) 1993-01-29 1995-03-07 Minnesota Mining And Manufacturing Company Process for preparing quinoline amines
US5352784A (en) 1993-07-15 1994-10-04 Minnesota Mining And Manufacturing Company Fused cycloalkylimidazopyridines
US5648516A (en) * 1994-07-20 1997-07-15 Minnesota Mining And Manufacturing Company Fused cycloalkylimidazopyridines
US5525606A (en) * 1994-08-01 1996-06-11 The United States Of America As Represented By The Department Of Health And Human Services Substituted 06-benzylguanines and 6(4)-benzyloxypyrimidines
DE19505168A1 (de) * 1995-02-16 1996-08-22 Boehringer Mannheim Gmbh Spezifische Lipidkonjugate von Nucleosid-Diphosphonaten und deren Verwendung als Arzneimittel
US5624677A (en) 1995-06-13 1997-04-29 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
US5741908A (en) * 1996-06-21 1998-04-21 Minnesota Mining And Manufacturing Company Process for reparing imidazoquinolinamines
US5693811A (en) 1996-06-21 1997-12-02 Minnesota Mining And Manufacturing Company Process for preparing tetrahdroimidazoquinolinamines
DE19637209B4 (de) * 1996-09-12 2006-12-14 Siemens Ag Verfahren zum Steuern des Antriebsstrangs eines Kraftfahrzeugs und integrierte Antriebsstrangsteuerung
KR100518903B1 (ko) 1996-10-25 2005-10-06 미네소타 마이닝 앤드 매뉴팩춰링 캄파니 Ｔｈ2 매개 질병 및 관련 질병의 치료용 면역 반응 조절 화합물
WO1999024432A1 (fr) * 1997-11-12 1999-05-20 Mitsubishi Chemical Corporation Derives de purine et medicament les renfermant en tant qu'ingredient actif
NZ504800A (en) 1997-11-28 2001-10-26 Sumitomo Pharma 6-Amino-9-benzyl-8-hydroxy-purine derivatives and interferon inducers, antiviral agents, anticancer agents and therapeutic agents for immunologic diseases thereof
US7001609B1 (en) * 1998-10-02 2006-02-21 Regents Of The University Of Minnesota Mucosal originated drug delivery systems and animal applications
US20020058674A1 (en) * 1999-01-08 2002-05-16 Hedenstrom John C. Systems and methods for treating a mucosal surface
TR200101943T2 (tr) * 1999-01-08 2002-04-22 3M Innovative Properties Company Bir immun cevap modifayeri ile mukoza ile ilgili durumların tedavisine yönelik formülasyonlar ve metodlar.
US6486168B1 (en) * 1999-01-08 2002-11-26 3M Innovative Properties Company Formulations and methods for treatment of mucosal associated conditions with an immune response modifier
CZ27399A3 (cs) * 1999-01-26 2000-08-16 Ústav Experimentální Botaniky Av Čr Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
ATE322494T1 (de) * 2000-01-07 2006-04-15 Universitaire Instelling Antwe Purin derivate, ihre herstellung und verwendung
US6733764B2 (en) * 2000-06-14 2004-05-11 Alain Martin Immunostimulator anti-cancer compounds and methods for their use in the treatment of cancer
AU2002212273B2 (en) * 2000-09-15 2007-06-14 Aaron Diamond Aids Research Centre System and method for optimizing drug therapy for the treatment of diseases
US20020127224A1 (en) * 2001-03-02 2002-09-12 James Chen Use of photoluminescent nanoparticles for photodynamic therapy
ATE348097T1 (de) * 2001-04-09 2007-01-15 Chiron Corp Guanidinoverbindungen als melanocortin-4-rezeptor (mc4-r) agonisten
US7157465B2 (en) * 2001-04-17 2007-01-02 Dainippon Simitomo Pharma Co., Ltd. Adenine derivatives
DE60206756T2 (de) * 2001-06-29 2006-07-13 CV Therapeutics, Inc., Palo Alto Purin derivate als a2b adenosin rezeptor antagonisten
US7241890B2 (en) * 2001-10-30 2007-07-10 Conforma Therapeutics Corporation Purine analogs having HSP90-inhibiting activity
CA2512161A1 (en) * 2003-01-28 2004-08-12 Shanghai Sunway Biotech Co., Ltd Hyperthermia oncolysis co-therapy
US20040265351A1 (en) * 2003-04-10 2004-12-30 Miller Richard L. Methods and compositions for enhancing immune response
WO2005016235A2 (en) * 2003-04-14 2005-02-24 The Regents Of The University Of California Combined use of impdh inhibitors with toll-like receptor agonists
US20050059613A1 (en) * 2003-07-08 2005-03-17 Bahram Memarzadeh Compositions and methods for the enhanced uptake of therapeutic agents through the bladder epithelium
WO2005020892A2 (en) * 2003-08-08 2005-03-10 Mitochroma Research, Inc. Pharmaceutical compositions and methods for metabolic modulation
EP1667694B1 (en) 2003-09-05 2010-04-28 Anadys Pharmaceuticals, Inc. Tlr7 ligands for the treatment of hepatitis c
JP2005089334A (ja) 2003-09-12 2005-04-07 Sumitomo Pharmaceut Co Ltd ８−ヒドロキシアデニン化合物
KR20060070572A (ko) * 2003-09-18 2006-06-23 콘포마 세러퓨틱스 코포레이션 Ｈｓｐ90-저해제로서의 신규 헤테로시클릭 화합물
FR2863890B1 (fr) 2003-12-19 2006-03-24 Aventis Pasteur Composition immunostimulante
JP2007526322A (ja) * 2004-03-02 2007-09-13 マサチューセッツ インスティテュート オブ テクノロジー ナノセル薬物送達系
WO2005092893A1 (ja) * 2004-03-26 2005-10-06 Dainippon Sumitomo Pharma Co., Ltd. ９置換−８−オキソアデニン化合物
CA2587676A1 (en) * 2004-11-19 2006-05-26 Institut Gustave Roussy Improved treatment of cancer by double-stranded rna
DK1879893T3 (da) 2005-03-21 2010-09-13 Ferrer Int Fremgangsmåde til fremstilling af 1-substituerede 1H-imidazo[4,5-c]quinolin-4-aminforbindelser og mellemprodukter dertil
US20070292418A1 (en) * 2005-04-26 2007-12-20 Eisai Co., Ltd. Compositions and methods for immunotherapy
ES2577514T3 (es) 2005-08-22 2016-07-15 The Regents Of The University Of California Antagonistas de TLR
WO2007034917A1 (ja) 2005-09-22 2007-03-29 Dainippon Sumitomo Pharma Co., Ltd. 新規なアデニン化合物
EP1939202A4 (en) 2005-09-22 2010-06-16 Dainippon Sumitomo Pharma Co NEW ADENINE CONNECTION
KR20080059595A (ko) 2005-09-27 2008-06-30 콜리 파마슈티칼 게엠베하 어댑터 올리고뉴클레오티드를 사용하는 ｔｌｒ-매개 면역반응의 조절
US20070100146A1 (en) * 2005-11-03 2007-05-03 Trevor Dzwiniel Process for the preparation of imidazo[4,5-c]-quinolin-4-amines
EP2029597A4 (en) * 2006-05-31 2011-11-23 Univ California purine analogs
EP2038290B1 (en) * 2006-07-07 2013-09-04 Gilead Sciences, Inc. Modulators of toll-like receptor 7
US7902187B2 (en) * 2006-10-04 2011-03-08 Wyeth Llc 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
TW200831104A (en) * 2006-10-04 2008-08-01 Pharmacopeia Inc 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
ES2552471T3 (es) * 2007-02-07 2015-11-30 The Regents Of The University Of California Conjugados de agonistas de TLR sintéticos y usos de los mismos
CA2691444C (en) * 2007-06-29 2016-06-14 Gilead Sciences, Inc. Purine derivatives and their use as modulators of toll-like receptor 7
JP2011500716A (ja) * 2007-10-16 2011-01-06 ギリアード・パロ・アルト・インコーポレイテッド Ａ３アデノシン受容体アンタゴニスト
EA201001264A1 (ru) 2008-02-07 2011-04-29 Дзе Регентс Оф Дзе Юниверсити Оф Калифорния Способ лечения заболеваний мочевого пузыря с помощью активатора tlr7
WO2010088924A1 (en) * 2009-02-06 2010-08-12 Telormedix Sa Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration
KR20110117705A (ko) 2009-02-11 2011-10-27 더 리전트 오브 더 유니버시티 오브 캘리포니아 톨-유사 수용체 조정제 및 질병의 치료
US8962652B2 (en) * 2009-10-22 2015-02-24 Gilead Sciences, Inc. Derivatives of purine or deazapurine useful for the treatment of (inter alia) viral infections
WO2011134669A1 (en) * 2010-04-30 2011-11-03 Telormedix Sa Methods for inducing an immune response
NZ603155A (en) * 2010-04-30 2014-06-27 Telormedix Sa Phospholipid drug analogs
US20130202629A1 (en) * 2010-04-30 2013-08-08 The Regents Of The University Of California Uses of phospholipid conjugates of synthetic tlr7 agonists
ES2458355T3 (es) * 2010-09-01 2014-05-05 Novartis Ag Adsorción de inmunopotenciadores sobre sales metálicas insolubles
US20120083473A1 (en) * 2010-09-21 2012-04-05 Johanna Holldack Treatment of conditions by toll-like receptor modulators

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004029054A1 (ja) * 2002-09-27 2004-04-08 Sumitomo Pharmaceuticals Company, Limited 新規アデニン化合物及びその用途

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9359360B2 (en) 2005-08-22 2016-06-07 The Regents Of The University Of California TLR agonists
US9050376B2 (en) 2007-02-07 2015-06-09 The Regents Of The University Of California Conjugates of synthetic TLR agonists and uses therefor
US11697851B2 (en) 2016-05-24 2023-07-11 The Regents Of The University Of California Early ovarian cancer detection diagnostic test based on mRNA isoforms
JP7159295B2 (ja) 2017-08-16 2022-10-24 ブリストル－マイヤーズ スクイブ カンパニー 免疫刺激因子トル様受容体７（ｔｌｒ７）アゴニストとしての、６－アミノ－７，９－ジヒドロ－８ｈ－プリン－８－オン誘導体
JP2020531472A (ja) * 2017-08-16 2020-11-05 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 免疫刺激因子トル様受容体７（ｔｌｒ７）アゴニストとしての、６−アミノ−７，９−ジヒドロ−８ｈ−プリン−８−オン誘導体
JP2020531469A (ja) * 2017-08-16 2020-11-05 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 三環式基を有するトル様受容体７（ｔｌｒ７）アゴニスト、そのコンジュゲート、ならびにそれらの方法および使用
JP7194170B2 (ja) 2017-08-16 2022-12-21 ブリストル－マイヤーズ スクイブ カンパニー 三環式基を有するトル様受容体７（ｔｌｒ７）アゴニスト、そのコンジュゲート、ならびにそれらの方法および使用
JP2023011643A (ja) * 2017-08-16 2023-01-24 ブリストル－マイヤーズ スクイブ カンパニー 免疫刺激因子トル様受容体７（ｔｌｒ７）アゴニストとしての、６－アミノ－７，９－ジヒドロ－８ｈ－プリン－８－オン誘導体
JP7474820B2 (ja) 2017-08-16 2024-04-25 ブリストル－マイヤーズ スクイブ カンパニー 免疫刺激因子トル様受容体７（ｔｌｒ７）アゴニストとしての、６－アミノ－７，９－ジヒドロ－８ｈ－プリン－８－オン誘導体
JP2021501765A (ja) * 2017-11-06 2021-01-21 サントル ナショナル ドゥ ラ ルシェルシュ シアンティフィック キサンチン誘導体及びｂｅｔタンパク質のブロモドメインの阻害剤としてのその使用
JP7254075B2 (ja) 2017-11-06 2023-04-07 サントル ナショナル ドゥ ラ ルシェルシュ シアンティフィック キサンチン誘導体及びｂｅｔタンパク質のブロモドメインの阻害剤としてのその使用
JPWO2020204173A1 (https=) * 2019-04-05 2020-10-08
JPWO2020204172A1 (https=) * 2019-04-05 2020-10-08
WO2020204173A1 (ja) * 2019-04-05 2020-10-08 大日本住友製薬株式会社 水溶性アジュバントおよびそれを含有する組成物
JP7539867B2 (ja) 2019-04-05 2024-08-26 住友ファーマ株式会社 水溶性アジュバント
JP7573516B2 (ja) 2019-04-05 2024-10-25 住友ファーマ株式会社 水溶性アジュバントおよびそれを含有する組成物

Also Published As

Publication number Publication date
IL214572A0 (en) 2011-09-27
US20100210598A1 (en) 2010-08-19
AU2010214112B2 (en) 2015-04-09
IL214572A (en) 2015-04-30
WO2010093436A2 (en) 2010-08-19
WO2010093436A3 (en) 2010-11-11
BRPI1008383A2 (pt) 2016-02-23
US8729088B2 (en) 2014-05-20
SG173617A1 (en) 2011-09-29
EA019768B1 (ru) 2014-06-30
CN102439011A (zh) 2012-05-02
CA2752074A1 (en) 2010-08-19
CN102439011B (zh) 2016-05-04
EP2396328A2 (en) 2011-12-21
ZA201106268B (en) 2013-02-27
MX2011008500A (es) 2011-09-26
EP2607365A1 (en) 2013-06-26
AU2010214112A1 (en) 2011-09-01
KR20110117705A (ko) 2011-10-27
EA201101165A1 (ru) 2012-04-30

Similar Documents

Publication Publication Date Title
CN102439011B (zh) Toll样受体调节剂和疾病的治疗
AU2008227128B2 (en) Conjugates of synthetic TLR agonists and uses therefor
CN103221067B (zh) 磷脂药物类似物
US20200223841A1 (en) Novel therapeutic agents for the treatment of hbv infection
EP2563366A2 (en) Uses of phospholipid conjugates of synthetic tlr7 agonists
JP2009504803A (ja) Ｔｌｒアゴニスト
US20130190494A1 (en) Purine analogs
US20200165239A1 (en) Protein kinase inhibitors, preparation method and medical use thereof
WO2012038058A1 (en) Treatment of conditions by toll-like receptor modulators
HK1170226A (en) Toll-like receptor modulators and treatment of diseases
BRPI0807196B1 (pt) Compostos 6-amino-8-hidróxipurin-9-ilbenzil substituídos, e, usos dos mesmos
HK40009256B (en) Novel therapeutic agents for the treatment of hbv infection
HK1177886B (en) Conjugates of synthetic tlr agonists and uses therefor
HK1138767B (en) Conjugates of synthetic tlr agonists and uses therefor

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121227

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20121227

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140602

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140825

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140901

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141201

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150417

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150618

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20160112